Amgen Inc: (NASD: AMGN)
$101.50
2.42 (2.44%)
Volume 3,283,906
Jun 18 04:00 PM ET
Zacks Rank: 3-Hold 
| #3 |
Full Company Report
Amgen Inc. discovers, develops and delivers innovative human therapeutics. A biotechnology pioneer, Amgen was one of the first companies to realize the new science's promise by bringing safe and effective medicines from lab, to manufacturing plant, to patient. Amgen therapeutics have changed the practice of medicine, helping millions of people around the world in the fight against cancer, kidney disease, rheumatoid arthritis, and other serious illnesses. With a deep and broad pipeline of potential new medicines, Amgen remains committed to advancing science to dramatically improve people's lives.
General Information
AMGEN INC
ONE AMGEN CENTER DRIVE
THOUSAND OAKS, CA 91320
Phone: 805 447-1000
Fax: 805-447-1010
Web: http://www.amgen.com
Email: investor.relations@amgen.com
| Industry | MED-BIOMED/GENE |
| Sector | Medical |
| Fiscal Year End | December |
| Last Reported Quarter | 03/31/2013 |
| Next EPS Date | 07/25/2013 |
Price and Volume Information
| Zacks Rank |  |
| Yesterday's Close | 99.08 |
| 52 Week High | 114.95 |
| 52 Week Low | 70.52 |
| Beta | 0.41 |
| 20 Day Moving Average | 3,262,946.50 |
| Target Price Consensus | 110.69 |
% Price Change
| 4 Week | -2.63 |
| 12 Week | 2.88 |
| YTD | 14.94 |
Share Information
| Shares Outstanding (millions) | 749.98 |
| Market Capitalization (millions) | 76,122.67 |
| Short Ratio | 2.29 |
| Last Split Date | 11/22/99 |
% Price Change Relative to S&P 500
| 4 Week | -1.61 |
| 12 Week | -2.60 |
| YTD | -0.92 |
Dividend Information
| Dividend Yield | 1.85% |
| Annual Dividend | $1.88 |
| Payout Ratio | 0.28 |
| Change in Payout Ratio | 0.19 |
| Last Dividend Payout / Amount | 05/14/2013 / $0.47 |
EPS Information
| Current Quarter EPS Consensus Estimate | 1.68 |
| Current Year EPS Consensus Estimate | 7.20 |
| Estimated Long-Term EPS Growth Rate | 8.40 |
| Next EPS Report Date | 07/25/2013 |
Consensus Recommendations
| Current (1=Strong Buy, 5=Strong Sell) | 2.18 |
| 30 Days Ago | 2.13 |
| 60 Days Ago | 2.04 |
| 90 Days Ago | 2.04 |
Fundamental Ratios
P/E
| Current FY Estimate | 14.11 |
| Trailing 12 Months | 14.86 |
| PEG Ratio | 1.68 |
Price Ratios
| Price/Book | 3.90 |
| Price/Cash Flow | 12.64 |
| Price / Sales | 4.36 |
Current Ratio
| 03-31-13 | 5.58 |
| 12-31-12 | 3.81 |
| 09-30-12 | 3.90 |
Net Margin
| 03-31-13 | 26.33 |
| 12-31-12 | 25.17 |
| 09-30-12 | 26.70 |
Inventory Turnover
| 03-31-13 | 1.07 |
| 12-31-12 | 1.10 |
| 09-30-12 | 1.08 |
EPS Growth
| vs. Previous Year | 22.64% |
| vs. Previous Quarter | 40.29% |
ROE
| 03-31-13 | 27.36 |
| 12-31-12 | 26.41 |
| 09-30-12 | 26.11 |
Quick Ratio
| 03-31-13 | 5.05 |
| 12-31-12 | 3.48 |
| 09-30-12 | 3.57 |
Pre-Tax Margin
| 03-31-13 | 28.57 |
| 12-31-12 | 29.01 |
| 09-30-12 | 30.55 |
Debt-to-Equity
| 03-31-13 | 1.23 |
| 12-31-12 | 1.26 |
| 09-30-12 | 1.21 |
Sales Growth
| vs. Previous Year | 4.69% |
| vs. Previous Quarter | -4.14% |
ROA
| 03-31-13 | 9.95 |
| 12-31-12 | 9.64 |
| 09-30-12 | 9.78 |
Operating Margin
| 03-31-13 | 30.44 |
| 12-31-12 | 29.47 |
| 09-30-12 | 29.91 |
Book Value
| 03-31-13 | 26.04 |
| 12-31-12 | 24.84 |
| 09-30-12 | 25.82 |
Debt to Capital
| 03-31-13 | 55.06 |
| 12-31-12 | 55.77 |
| 09-30-12 | 54.69 |
